Leveraging Patient Engagement & the Role of Advocacy.

Slides:



Advertisements
Similar presentations
Building Civic Life on the New Frontier Submitted by:- Maulika. R. Kapoori ( )
Advertisements

Stop. Think. Connect. National Cybersecurity Awareness Campaign October 2010.
Cancer Research UK strategy and funding Simon Vincent.
OUR STRATEGIC PLANNING JOURNEY. The Department of Medicine Strategic Plan  Our roadmap for the future  It will shape and guide what the Department of.
Patient Advocacy Bruce MacDonald JHYSF Meet the Sarcoma Experts MGH - Nov. 22, 2008.
Boosting Non State Actor participation in CAADP Yaoundé 24 th March 7 Th CAADP PP CAADP NSA Coordination Task Team.
RARE ACTION NETWORK ® Presentation by NORD June 16, 2014.
Human Rights Projects: Guidelines for Scientists and Human Rights Organizations HITA workshop October 14, 2012.
Prize4Life: Inducement Prizes for ALS (Lou Gehrig’s Disease) Nicole Szlezak Member, Board of Directors Prize4Life.
ASQ 2015 Brand Transformation Raise the Voice of Quality!
The International CardiOncology Society An Update for 2014 Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research.
Grand Challenges: Overview Gary L. Darmstadt, MD, MS Senior Fellow Bill & Melinda Gates Foundation IOM Forum: Investing in Young Children Globally Sao.
Influencing Change in Research, Treatment Protocols, and New Drug Development.
NCI Center for Global Health Jo Anne Zujewski, M.D. September 11, 2014 Dar es Salaam, Tanzania.
Northwestern Collaboration Services Communications & Training Plan
© 2014 Medidata Solutions, Inc. Can Big Data/Real World Data Cure Life Science’s R&D Malaise? Glen de Vries Founder and President.
California Senior Fall Prevention Coalitions Terri Restelli-Deits, MSW Area Agency on Aging Serving Napa and Solano CA Fall Prevention Summit / December.
Supporting research and patient outreach for FacioScapuloHumeral Muscular Dystrophy (FSHD), one of the most common forms of muscular dystrophy. Progress.
Rallying for Action on NCDs Lynda Williams Medical Consultant Healthy Caribbean Coalition Cancer Workshop Healthy Caribbean 2012 May 27, 2012, Wyndham.
ADAMOS ADAMOU, MEDICAL ONCOLOGIST MEMBER OF THE EUROPEAN PARLIAMENT.
Crowdsourcing Clinical Drug Development in a transparent model Tomasz Sablinski M.D., Ph.D. Founder, Transparency Life Sciences Head of Development, Celtic.
Making the Ethical Feasible: Assuring future access to care to those who sero-convert in microbicide trials Anna Forbes, MSS XVI.
1 Intel ® Teach ST & ITA Summit Copyright © 2010 Intel Corporation. All rights reserved. Intel, the Intel logo, and the Intel Teach Program are trademarks.
Analysis, modelling and sensing of both physiological and environmental factors for the customized and predictive self-management of Asthma H2020-PHC-2014-single-stage.
European Patients’ Forum Regional Advocacy Seminar Budapest October 2010 Welcome by The Medtronic Foundation.
BREAST HEALTH GLOBAL INITIATIVE(BHGI) SUPPORTIVE CARE GUIDELINES& THEIR ROLE IN ADVOCACY : The Uganda Experience Gertrude Nakigudde Patient Advocate Uganda.
World Wide Prostate cancer coalition Moving forward together : The solution T. Hudson Geneva,
How to Build a Network. Overview: Recruiting and Mobilizing Community Organizations Together, the Steering Committee and the Community Action Team: Identify.
Experimental Cancer Medicine – the future of cancer care Rosie Davies (LECMC RP based at RLUH) Janet Davies (LECMC RP based at CCO)
Overview of Advocacy, Communication, and Social Mobilization.
Web 2.0 in Business Networking | Public Relations | Collaboration.
Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.
Saïd Business School 1-3 September The Journey So Far… A Personal Perspective Professor Stig Pramming, Novo Nordisk.
© 2011 Global Genes Project r8 R.A.R.E Project presents – The RARE Fund.
Introducing… the Sustainable Energy 4 All Action Accelerator! Adam Cooper Senior Manager, Accenture Sustainability Services United Nations Global Compact.
WORLD ALLIANCE OF YMCAS ASIA AND PACIFIC ALLIANCE OF YMCAS (APAY) GENERAL ASSEMBLY – SEPTEMBER 2011.
1 Allergy & Asthma Network Asthma Coalitions Summit 2015 Tonya A. Winders, MBA President & CEO.
Leukaemia & Lymphoma Research David Henderson. Where we started.
Role of the Drug Project Team in Formulating the Initial Development Plan of NCI-IND agents Jeff Moscow, MD IDB, CTEP.
Massey 101 Defining the Massey Difference. Defining Massey.
2013 Fall Forum Improving Health Outcomes : Finding Options for Better Access to Care Health Policy Advocacy & Action Plan Development.
Presentation to CSA November 24 th, 2015 Meredith Kushnir, Marketing and Community Engagement Coordinator, CICMH.
© Copyright Showeet.com Philanthropy and Community Collaboration: Working Together to Fund Change December 4, 2015 Natalie Ross Global Philanthropy Director.
Chapter 8 The Social Enterprise: From Recruiting to Problem Solving and Collaboration.
Overview and Strategic Direction Presenter: April Golden February 24, 2016.
Building capacity and leadership to identify unwarranted variation and how technology can support this. Stacey McCann, Assistant Head.
Population Health and Health Information Technology HTM520, National University Kathleen Sullivan, July 2012.
Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.
Dr. Sabine Brookman-May, MD, PhD Regional Therapeutic Area Expert Oncology (Europe, Middle East, Africa) - Janssen R&D Improving patients involvement in.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
This study is funded by a contract from the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. Cancer.
Better Science, Better Health: New Healthcare Models
S1400 OVERVIEW / BACKGROUND
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
Finland, a Global Testbed for Personalized Cancer Research?
Non For Profit Model for Rare Disease Therapy Development
Enhancing Patient Care in Advanced NSCLC Through Clinician-Patient Partnership.
Progenics Pharmaceuticals – Prophix story
Innovative Medicines Initiative:
The Different Phases Of Clinical Trials
Clinical and Translational Science Awards Program
A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer  David R. Spigel,
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
George Blumenschein, MD, John V. Heymach, MD, PhD 
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
The Network of European Patient Advocacy Groups is the only umbrella organization for patient groups committed to gynaecological cancers. Established in.
Mitotic Inhibitors Journal of Thoracic Oncology
Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.
Presentation transcript:

Leveraging Patient Engagement & the Role of Advocacy

Lung Cancer is a Global Epidemic. It requires a global solution. 2 OVERVIEW Collaboration with all stakeholders, especially patients, is required to transform lung cancer into a survivable disease.

HOW can we accomplish this goal? We all must commit to helping all patients/survivors and those yet to be diagnosed. Through patient education, awareness and advocacy and in collaboration/partnership with the leaders in oncology, technology, science, medicine and philanthropy, we can raise awareness and fund research that will lead to better, more effective detection and treatments. We are convinced that personalized medicine is the gateway to success and we can power progress by involving patients, donors, clinicians, pharmaceutical and biotech companies, payers, government and public and private enterprise. OVERVIEW

Educated and Informed Patients Are Empowered Patients & Empowered Patients Survive Longer! OVERVIEW

TECHNOLOGY 5 Most advocacy groups use technology to educate and inform their patient constituency via webex or on-line summits.

PATIENT COMMUNITIES 6 There are a multitude of patient communities, blogs and information sharing platforms for patients to engage with their peers.

SOCIAL MEDIA 7 Social media has become a daily communication tool to mobilize efforts, help raise awareness and educate the world that anyone can get lung cancer.

COLLABORATIONS 8 There are also several key collaborations happening in the lung cancer community to the benefit of patients. Lung Cancer Ponatinib Trial Molecular Testing Phase A phase II study of ponatinib in cohorts of patients with lung cancer preselected using different candidate predictive biomarkers (Principal Investigator: D. Ross Camidge, MD PhD)

ADVOCACY AWARENESS 9 Working together, we can make a difference.